Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?

Leukemia Research

Volumn 34, Issue 9, 2010, Pages 1242-1245

  Galván, Ana Belén ^a,b   Mallo, Mar ^a,b   Arenillas, Leonor ^a   Salido, Marta ^a   Espinet, Blanca ^a   Pedro, Carmen ^a   Florensa, Lourdes ^a   Serrano, Sergi ^a   Solé, Francesc ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

5q deletion; Acute myeloid leukemia; FISH; Karyotype; Monosomy 5; Myelodysplastic syndrome

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION 5; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 5; CHROMOSOME TRANSLOCATION 7; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MONOSOMY; MONOSOMY 5; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

EID: 77955255893     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.022     Document Type: Article

References (13)

1. Swerdlow S., Campo E., Harris N.L., et al. World Health Organization classification: tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon.
2. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
3. Kantarjian H., O'Brien S., Ravandi F., et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?. Cancer 2009, 115:5202-5209.
4. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
5. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
6. Mallo M., Arenillas L., Espinet B., et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica 2008, 93:1001-1008.
7. Herry A., Douet-Guilbert N., Morel F., et al. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML. Eur J Haematol 2007, 78:457-467.
8. Trost D., Hildebrandt B., Beier M., et al. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. Cancer Genet Cytogenet 2006, 165:51-63.
9. Gondek L.P., Tiu R., Haddad A.S., et al. Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. Leukemia 2007, 21:2058-2061.
10. Makishima H., Rataul M., Gondek L.P., et al. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk Res 2010, 34:447-453.
11. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
12. Haase D., Schanz J., Tuechler H., et al. Updated cytogenetic risk features in MDS. Leuk Res 2009, 33:S9-S10.
13. Chun K., Hagemeijer A., Iqbal A., et al. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. Leuk Res 2010, 34:160-165.